1.241 articles found

The effect of polygenic risk score on PD risk and phenotype in <i>LRRK2</i> G2019S and <i>GBA1</i> carriers.

Goldstein O, Shani S, Gana-Weisz M, Elkoshi N, Casey F, Sun YH, Chandratre K, Cedarbaum JM, Blauwendraat C, Bar-Shira A, Thaler A, Gurevich T, Mirelman A, Giladi N, Orr-Urtreger A, Alcalay RN.

J Parkinsons Dis · 2025-01-17

DOI: 10.1177/1877718x241310722PMID: 39973498

In vivo self-assembled siRNAs within small extracellular vesicles attenuate LRRK2-induced neurodegeneration in Parkinson's disease models.

Zhang L, Chen P, Chen T, Lin L, Ji X, Liu J, Huang H, Saravanan T, Fuehrer H, Ross CA, Smith WW, Pei Z, Chen X.

J Control Release · 2025-01-09

DOI: 10.1016/j.jconrel.2024.12.045PMID: 39722304

Exploring LRRK2-dependent Mechanisms in Parkinson's Disease Therapy.

Sharma V, Sharma S, Singh S, Singh TG.

CNS Neurol Disord Drug Targets · 2025-01-01

DOI: 10.2174/0118715273377507250320035243PMID: 40231505

The design and development of LRRK2 inhibitors as novel therapeutics for Parkinson's disease.

Bai X, Zhu J, Chen Y, Sun H.

Future Med Chem · 2024-12-24

DOI: 10.1080/17568919.2024.2444875PMID: 39717965

α-Synuclein Gene Hypomethylation in LRRK2 Parkinson's Disease Patients.

de Mena L, Parés G, Garrido A, Pilco-Janeta DF, Fernández M, Pérez J, Tolosa E, Cámara A, Valldeoriola F, Ezquerra M, Martí MJ, Fernández-Santiago R, Barcelona LRRK2 Study Group.

Mov Disord · 2024-12-23

DOI: 10.1002/mds.30094PMID: 39711195

Multimodal oculomotor assessment reveals prodromal markers of Parkinson's disease in non-manifesting LRRK2 G2019S mutation carriers.

Riek HC, Visanji NP, Pitigoi IC, Di Luca DG, Armengou-Garcia L, Ahmed N, Perkins JE, Brien DC, Huang J, Coe BC, Huang J, Ghate T, Lang AE, Marras C, Munoz DP.

NPJ Parkinsons Dis · 2024-12-19

DOI: 10.1038/s41531-024-00840-wPMID: 39702611

LRRK2 mutation contributes to decreased free water in the nucleus basalis of Meynert in manifest and premanifest Parkinson's disease.

Wang C, Wang S, Zhou C, Wu C, Yang S, Xu X, Zhang M, Huang P.

J Neurol · 2024-12-12

DOI: 10.1007/s00415-024-12811-5PMID: 39666095

Associations between basal forebrain volume and cognitive decline in GBA and LRRK2 mutation carriers from asymptomatic stages to Parkinson’s disease

Schumacher J, Teipel S, Storch A.

Alzheimer's & dementia : the journal of the Alzheimer's Association · 2024-12-01

Exploring environmental modifiers of LRRK2-associated Parkinson's disease penetrance: An exposomics and metagenomics pilot study on household dust.

Talavera Andújar B, Pereira SL, Busi SB, Usnich T, Borsche M, Ertan S, Bauer P, Rolfs A, Hezzaz S, Ghelfi J, Brüggemann N, Antony P, Wilmes P, Klein C, Grünewald A, Schymanski EL.

Environ Int · 2024-11-16

DOI: 10.1016/j.envint.2024.109151PMID: 39571299

Molecular dynamics studies reveal the structural impacts of LRRK2 R1441C and LRRK2 D1994A mutations in Parkinson's disease.

Rahman RA, Zaman B, Islam MS, Rashid MH.

Biochem Biophys Rep · 2024-11-12

DOI: 10.1016/j.bbrep.2024.101866PMID: 39610832

Immunomodulatory properties of hempseed oligopeptides in an LRRK2-associated Parkinson's disease animal model.

Torrecillas-Lopez M, Rivero-Pino F, Trigo P, Toscano-Sanchez R, Gonzalez-de la Rosa T, Villanueva A, Millan-Linares MC, Montserrat-de la Paz S, Claro-Cala CM.

Food Funct · 2024-11-11

DOI: 10.1039/d4fo03167aPMID: 39435853

Clinical features and progression of Parkinson's disease with LRRK2 variants: A prospective study.

Song T, Zhou X, Wang C, Wu H, Yan X, Guo J, Tang B, Lei L, Xu Q, Parkinson's Disease & Movement Disorders Multicenter Database and Collaborative Network in China (PD‐MDCNC).

Ann Clin Transl Neurol · 2024-11-11

DOI: 10.1002/acn3.52244PMID: 39529459